Loading organizations...
§ Private Profile · Mason, OH, USA
Medtech company develops CardioFlux biomagnetic imaging for healthcare providers, diagnosing cardiovascular disease in acute care.
Based in Mason, Ohio, Genetesis is a commercial-stage medical technology company that develops noninvasive biomagnetic imaging systems to detect and localize cardiovascular disease. The company's primary product, the CardioFlux magnetocardiograph, utilizes biomagnetism, data science, machine learning, and cloud-based analytics to generate 3D maps of the heart's electrical activity for acute care settings. Operating with a workforce of 30 employees, the enterprise has raised $40 million in total venture funding to commercialize its diagnostic hardware and software services for emergency departments and cardiologists. Genetesis is backed by prominent investors including Mark Cuban, TDK Ventures, and CincyTech, and it has partnered with major healthcare providers such as the Cleveland Clinic and Christ Hospital for clinical trials and commercial deployment. The organization was founded in 2013 by Peeyush Shrivastava, Vineet Erasala, Manny Setegn, and Chandan Srivastava.
Genetesis has raised $36.2M across 4 funding rounds.
Genetesis has raised $36.2M in total across 4 funding rounds.
Genetesis has raised $36.2M across 4 funding rounds. Most recently, it raised $18.0M Series C in October 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2022 | $18M Series C | Mithril Capital Management | Alumni Ventures, Cincy Tech, Eclipse Ventures, OrbiMed, Sonder Capital, Cercano Management, CincyTech USA, JobsOhio Growth Capital, Ohio Innovation Fund | Announced |
| Apr 1, 2020 | $9M Series B | — | TDK Ventures, Mark Cuban, CincyTech USA, Ohio Innovation Fund | Announced |
| Jun 1, 2018 | $8M Series A | John M. Rice | Cincy Tech, OrbiMed, Ohio Innovation Fund, Mark Cuban, Raptor Group | Announced |
| Nov 14, 2016 | $1.2M Seed | John M. Rice, Mark Cuban | Danmar Capital, LOUD Capital, WS Investments | Announced |
Genetesis has raised $36.2M in total across 4 funding rounds.
Genetesis's investors include Mithril Capital Management, Alumni Ventures, Cincy Tech, Eclipse Ventures, OrbiMed, Sonder Capital, Cercano Management, CincyTech, JobsOhio Growth Capital, Ohio Innovation Fund, TDK Ventures, Mark Cuban.
Genetesis is a commercial-stage medical technology company developing noninvasive biomagnetic imaging for cardiac diagnostics, specifically the CardioFlux Magnetocardiograph (MCG) paired with the Faraday Analytical Cloud (FAC).[1][2][4] It serves clinicians and hospitals by addressing myocardial ischemia and coronary artery disease triage in acute care settings, such as emergency departments handling eight million annual chest pain visits, aiming to serve as the ultimate rule-out test alongside EKGs and troponins without radiation, exercise, or specialized rooms.[1][4] The platform solves inefficient chest pain triage by delivering quick magnetic field maps processed into actionable insights via cloud-based machine learning, integrating into clinical workflows to reduce ER length of stay; the company has raised over $25M in venture funding, secured FDA 510(k) clearance, and achieved commercial availability.[2][4]
Genetesis was founded in 2013 in Mason, Ohio, by three co-founders: Peeyush Shrivastava (CEO), with 8+ years as a serial medtech entrepreneur and Biomedical Science background; Vineet (COO), expert in medical device lifecycle and commercial strategy; and Emmanuel (CTO), with nearly 10 years in software and IT operations.[2][4][5] The idea emerged from advancing magnetocardiography (MCG)—a 40-year-old technology previously limited by bulky SQUID hardware—into a practical, high-density commercial tool for cardiac care.[2][6] Early days included bootstrapping from Thompson Library in summer 2016, posting "Yes We're Open" notes to build momentum, leading to pivotal FDA clearance for CardioFlux and FAC, plus $9.2M Series B funding in 2020 from TDK Ventures, Mark Cuban Companies, CincyTech, and others.[1][2][4]
Genetesis rides the precision cardiology and noninvasive diagnostics trend, capitalizing on rising demand for radiation-free, rapid triage amid 8M annual U.S. chest pain ER visits and global cardiovascular disease burden.[4] Timing aligns with advances in magnetic sensing (leveraging TDK expertise) and cloud AI, enabling scalable deployment in resource-strapped hospitals post-COVID.[4][6] Market forces like value-based care, ER overcrowding, and medtech investor focus on outcomes favor it, positioning Genetesis to influence ecosystems by standardizing MCG in acute care, potentially freeing hospital resources and improving patient flow.[1][4]
Genetesis is poised for expanded adoption as hospitals prioritize efficient, tech-driven cardiac triage, with next steps likely including broader commercialization, additional FDA indications, and partnerships to embed CardioFlux in workflows.[1][2] Trends like AI-enhanced imaging and precision health will accelerate growth, evolving its influence from niche innovator to standard-of-care enabler in ischemia detection. This builds on its rule-out test ambition, redefining diagnostics from Genetesis's library-start hustle to clinical powerhouse.[2][4]